Phase 1 Parkinson's Disease Trial, Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The person is Chinese, meaning all four of their grandparents were born in China.
- The person has been diagnosed with idiopathic Parkinson's disease (Parkinson's disease with no known cause), confirmed using a standard set of medical diagnostic guidelines called the UK PD Society Brain Bank Criteria.
- The person's Parkinson's disease severity falls within a specific range on a standard rating scale, measured both when their medication is working and when it is not (confirm with trial site for exact details).
- The person experiences clear and predictable changes in their ability to move throughout the day — including predictable periods in the morning where their Parkinson's symptoms are worse — that have been causing significant difficulties in daily life for at least the past 3 months, as assessed by the trial doctor.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- The person has taken certain Parkinson's medications called dopamine agonists (in tablet or skin patch form) within the 4 weeks before the screening visit.
- The person has had brain surgery related to Parkinson's disease, such as pallidotomy, thalamotomy, deep brain stimulation, or cell transplant procedures.
- The person has another medical condition that requires treatment that takes priority over Parkinson's disease, or that is likely to interfere with the trial treatment or make it difficult to follow the trial requirements.
- The person has received Traditional Chinese Medicine treatment within the 4 weeks before the screening visit.
- There may be additional criteria not listed here that the trial site will assess.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Email contact via H. Lundbeck A/S, LundbeckClinicalTrials@Lundbeck.com
Phone: +45 36301311
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Treatment-emergent Adverse Events (TEAEs); Area Under the Plasma Concentration-time Curve From Zero to Last Quantifiable Concentration (AUC0-tlast) of Lu AF28996; Maximum Observed Plasma Concentration (Cmax) of Lu AF28996; Time to Reach Cmax (Tmax) of Lu AF28996
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.